argenx reports fourth quarter business update and full year 2016 financial results
March 15, 2017 02:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Management to host conference call...
argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2016 Financial Results on March 15, 2017
March 09, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
8 March...
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
March 06, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
-Anti-ApoC3 antibody developed as part...
argenx announces intention to conduct a registered public offering in the United States
March 01, 2017 13:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx to Present at Cowen & Co 37th Annual Health Care conference
February 28, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium-...
argenx announces extension of therapeutic antibody alliance with Shire
February 27, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference
February 09, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium-...
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
January 09, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Topline data from the study...
argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine
December 29, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients
December 15, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...